Seegene, Shimadzu Ink Molecular Dx Pact | GenomeWeb
NEW YORK (GenomeWeb News) – Seegene and Shimadzu jointly announced today that they will collaborate on developing molecular diagnostics tests that will run on Shimadzu’s MultiNA high-speed electrophoresis system.
 
Seegene makes the Seeplex family of PCR-based, multi-pathogen tests. The Rockville, Md.-based firm makes screening tests for STDs, respiratory viruses, human papillomavirus, sepsis, and pneumonia, it said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.